INNOVATION

Inspired and ambitious, our researchers are pioneers in cancer therapeutic development – focussed on developing our BRiDGECAR™ system, which combines our nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies.

If successful, we will be one step closer to our vision – targeted treatment for millions of cancer patients worldwide.

THE BRiDGECAR™ SYSTEM

CORE COMPONENT

CAR T-cells

We use the human T cell as our cancer cell killer because they are highly potent and can remain ready for action in the body permanently.

We have engineered these T cells into CAR T-cells to target cancer directly via our nfP2X7 derived antibody sequences.

MULTI-TARGETING

tumour antigens

We place the proprietary “Tag” on antibodies to direct the BRiDGECAR™ to multiple tumour targets.

The BRiDGECAR™ system is optimised to allow the targeting of multiple tumour antigens at the same time. An accepted tactic to increase treatment efficacy.

HOW IT WORKS

in the immune system

Our BRiDGECAR™ is engrafted into the patient’s immune system.

A specific mix of targeted antibodies designed for the cancer being treated is injected into the patient.

The antibodies engage the tumour cells and the BRiDGECAR™ engages these antibodies via the “Tag”.

 READ MORE ABOUT CAR T 
 READ MORE ABOUT nfP2X7 

WHY BRiDGECAR™?

BRiDGECAR™ has an advantage over competitors due to its dual functional capability:

  • It has a direct targeting function via nfP2X7 derived antibody sequences, and
  • It can attack cancer via additional BRiDGE antibodies, enhancing the cancer cell killing and minimising treatment resistance and patient relapse

BRiDGECAR™ incorporates industry leading advanced molecules that boost long-term cancer cell killing.

BRiDGECAR™ has the potential to treat most types of cancer.

BIOSCEPTRE’S BRiDGECAR™ DUAL-FUNCTIONALITY

The BRiDGECAR™ targets cancer both directly and via the BRiDGE™ antibodies.

BRiDGECAR™ T cells persist, hunting down and killing cancer cells between BRiDGE antibody treatments.

BRiDGECAR™ may provide ongoing tumour suppression via nfP2X7 after the administration of the BRiDGE antibodies has ceased.

Competitor approaches cannot do this.

TARGETED ANTIBODY THERAPY

We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, monoclonal, bispecifics, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs) in addition to our CAR-T program.
READ MORE ABOUT TARGETED ANTIBODY THERAPY